The vasculopathy of autosomal dominant polycystic kidney disease: Insights from animal models  by Arnaout, M. Amin
Kidney International, Vol. 58 (2000), pp. 2599–2610
NEPHROLOGY FORUM
The vasculopathy of autosomal dominant polycystic kidney
disease: Insights from animal models
Principal discussant: M. Amin Arnaout
Renal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
uncle also died at an early age of an MI. The patient’s younger
sister was later screened for cerebral aneurysms and the test
was negative. The patient’s two young children have not been
screened for ADPKD.
DISCUSSION
Dr. M. Amin Arnaout (Chief, Renal Unit, Massachu-
setts General Hospital, and Professor of Medicine, Har-
vard Medical School, Boston, Massachusetts, USA): This
case represents one of the most feared outcomes in a
patient with ADPKD, the fatal rupture of a cerebral aneu-
rysm. It took place in a young patient with well-controlled
blood pressure, moderate renal dysfunction, and no fam-CASE PRESENTATION
ily history of aneurysms. This case also raises issues relat-
A 37-year-old white man with autosomal dominant polycys-
ing to the spectrum of the vascular lesions in ADPKD,tic kidney disease (ADPKD) was admitted to Boston’s Beth
and the indications for prospective imaging studies inIsrael Hospital with sudden severe headache of two-hour dura-
tion. He was unconscious on admission. Emergency angiogra- asymptomatic patients with no family history. Two re-
phy revealed a ruptured 15 mm cerebral aneurysm. Emergency cent Nephrology Forums have expertly addressed the
surgery to clip the aneurysm was unsuccessful, and the patient extrarenal manifestations and complications of ADPKD
died 36 hours after admission. His serum creatinine was 3.2
[1, 2]. In today’s presentation, I will provide an overviewmg/dL on admission; the rest of his laboratory values were
of the progress made in the molecular genetics andwithin normal limits. A request for an autopsy was denied.
At age 20, the patient and his then 15-year-old sister had pathogenesis of ADPKD, focusing on new insights into
abdominal ultrasound examinations that revealed bilateral re- the genesis of the vasculopathy that were derived from
nal cysts, consistent with the diagnosis of ADPKD. At age 32, animal models of the disease.the patient had a sudden, relatively severe, acute myocardial
Autosomal dominant polycystic kidney disease, theinfarction (MI). Cardiac catheterization revealed three-vessel
most common inherited renal disease in patients on he-disease, and he subsequently underwent a triple coronary artery
bypass operation. Throughout his medical course, the patient’s modialysis, is one of the most common genetic diseases
blood pressure was in the 120/80 to 140/80 mm Hg range while he in humans. Bilateral renal cysts are the cardinal feature
was taking lisinopril, 10 mg/day, which was started after his MI. of ADPKD, but cysts in other ductal organs, such as theThe patient’s mother has ADPKD and end-stage renal dis-
liver and pancreas, are common. Renal cysts arise fromease, and she is on hemodialysis. She recently underwent unsuc-
fewer than 1% of nephrons and enlarge throughout thecessful renal transplantation. There is no known family history
of cerebral aneurysms. However, the mother had two cerebro- lifetime of an individual, culminating in end-stage renal
vascular accidents and recovered from both. The patient’s fa- disease in approximately 50% of affected individuals by
ther had an MI at age 32, but he lived to age 64. A paternal age 50. As today’s tragic case illustrates, ADPKD is also
a disease of blood vessels. Cardiovascular abnormalities
include vascular aneurysms that sometimes recur [3];Key words: PKD1 and PKD2 genes, polycystin, intracranial aneu-
rysms, cystogenesis. arterial dolichoectasias [4]; aortic root dilation [5]; and
dissections of intracerebral [6], coronary [7], aortic, tho-The Nephrology Forum is funded in part by grants from Amgen,
racic, iliac [8–11], and splenic [12] blood vessels. TheseIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
rated; AstraZeneca LP; and R & D Laboratories. vascular abnormalities are not always associated with
high blood pressure [13]. Intracranial aneurysms are ob-Ó 2000 by the International Society of Nephrology
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served in approximately 10% of asymptomatic adults chromosome 17 [31]. The ,68 kb human PKD2 gene
contains 15 exons and encodes a ,5.4 kb transcript [31].with ADPKD. Sudden rupture of these lesions is respon-
sible for death in approximately 20% of the cases. Clus- It does not contain unusual features similar to those pres-
ent in the human PKD1 gene. The mouse homologuetering of intracranial aneurysms has been described in
several ADPKD families, with the incidence of aneu- of PKD2 (Pkd2) maps to mouse chromosome 5 [35].
rysms rising to approximately 25% in asymptomatic pa-
The polycystin protein familytients in some families [14, 15]. Marked sclerosis of pre-
glomerular vessels also has been seen, even in early cases Polycystin-1 and polycystin-2, the proteins encoded by
PKD1 and PKD2, respectively, belong to a family ofwhen blood pressure and serum creatinine are still nor-
mal [16]. Diastolic dysfunction (prolonged peak early dia- proteins, five members of which have been described to
date (Fig. 1). Polycystin-1 is a 4302 amino acid 11-passstolic velocity deceleration time and isovolumetric relax-
ation time, and increased left-ventricular mass) has been plasma membrane protein with an apparent molecular
mass greater than 450 kD, and multiple potential glyco-detected in young normotensive ADPKD patients [17].
An increased incidence of cardiac valve defects also has sylation sites [36]. Mouse polycystin-1 is 4298 amino acids
long, with 79% amino acid identity to human polycystin-1been found in 9% to 25% of patients in some studies
[5, 18–20], but not found in others [17, 21]. Evidence [37]. The large extracellular region of polycystin-1 contains
a leucine-rich repeat, a C-type lectin domain, a cysteine-also suggests an elevated risk for cardiovascular morbid-
ity and mortality in ADPKD [22, 23]. rich low-density lipoprotein-A domain, and 16 PKD1
repeats, which are related to but distinct from immuno-
Genetic basis of ADPKD globulin repeats [38]. The PKD1 repeats are followed
by a receptor for egg jelly (REJ) domain, approximatelyAutosomal dominant polycystic kidney disease is caused
by mutations in two genes, PKD1 and PKD2, which are 1000 amino acids long, which ends in the first putative
transmembrane segment. The REJ domain is found inmapped to chromosomes 16p13.3 and 4ql3-p23, respec-
tively [24, 25]. Mutations in the PKD1 gene are responsi- the sea urchin sperm receptor for egg jelly [39], which
mediates the acrosomal reaction, a calcium-channel-ble for 85% to 90% of all cases of ADPKD; mutations
in PKD2 cause the disease in most of the remaining gated event, upon ligand binding. In polycystin-1, the
REJ domain is followed by 11 putative transmembranepatients. In humans and mice, PKD1 is closely linked to
TSC2, a gene responsible for a major form of tuberous (TM) regions. The C-tail contains a predicted coiled-coil
region that interacts in vitro with a proposed coiled-sclerosis [26]. In patients with mutations in PKD2, pro-
gression to end-stage renal failure is delayed by an aver- coil region in polycystin-2 [40]. These features suggest
potential roles for polycystin-1 in cell-cell and cell-matrixage of 10 years, in association with fewer renal cysts and
milder hypertension. In a small number of families, a third, interactions as well as in regulation of ion transport either
directly or through its association with polycystin-2, ayet-to-be-characterized gene, has been implicated [27].
The ,50 kb PKD1 gene contains 46 exons encoding putative ion channel [41]. The last six TM segments of
polycystin-1 are homologous to the six TM regions foundan ,14 kb mRNA. Seventy percent of the gene (from
exon 1 to intron 34) is replicated in at least three homolo- in each of the other four family members. Homology
also extends to the REJ domain found in polycystin-REJ.gous genes (HG) at an adjacent site on chromosome
16pl3.1. Although no evidence has shown that any of Polycystin-2 is 968 amino acids long, with an apparent
molecular mass of approximately 110 kD [41]. Its N- andthese homologous genes are translated into protein prod-
ucts [28], these genes, through gene conversion, could C-termini are cytoplasmic, and it has six (S1-S6) trans-
membrane segments with homology to the C-terminalpromote mutations in PKD1 [29]. A second mechanism
for increased mutability of human PKD1 might relate six TM region in polycystin-1, to the a-subunit of a large
group of voltage-activated calcium and sodium channels,to the presence of long polypurine·polypyrimidine tracts
in two introns capable of forming multiple non-B-DNA and to the store-operated transient receptor potential
channel (TRPC) subunits, where homology is limited tostructures [30]. These two features, the 59 duplications
[31] and the polypurine-polypyrimidine tracts [32], are the S5-6 region [42]. The S2-S5 and part of the linker
region between S5 and S6 interact with TRPC1 [42]. Thelacking in the mouse homologue of PKD1 (Pkd1), in
which no spontaneous mutations in PKD1 are known to polycystin-2 C-tail contains three functional regions, one
involved in localization to the endoplasmic reticulumoccur. The majority of PKD1 mutations [33], however,
are not accounted for by either of these two features. In [43], the second a predicted coiled-coil region that inter-
acts with the C-tail of polycystin-1 [40] and TRPC1 chan-addition, the age-dependent increase in mutant frequency
in primary cell clones isolated from the human renal nel [42], and a third calcium-binding EF-hand domain
that partially overlaps with a region that mediates homo-cortex has not been observed in mice. This suggests a
more general resistance to mutability in mouse cells [34]. dimerization [41]. Mouse polycystin-2 is 966 amino acids
long, with 91% identity to human polycystin-2 [35].The mouse homologue of PKD1 (Pkd1) maps to mouse
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Fig. 1. Schematic of the proposed structures for various polycystins. See text for details.
Three additional human genes, PKDL, PKDREJ, and duplicated region of PKD1 to date. In all regions of the
gene, mutations are roughly equally divided betweenPKD2L encode other polycystins. All three respective pro-
teins (polycystin-L, polycystin-REJ, and polycystin-2L) are missense and nonsense mutations, and frameshift muta-
tions. With rare exceptions, no two mutations are alike,homologous to polycystin-1 and -2 in the putative ion
transporting six-pass segment [44, 45]. Polycystin-L is and when they are, they appear to have arisen indepen-
dently [53, 54]; this finding suggests a high mutation ratelocalized to chromosome 10q24-25 [45]. It shows 71%
homology to polycystin-2 and 45% homology to polycys- in PKD1. Genomic deletions affecting PKD1 and the
adjacent TSC2 gene lead to a more severe cystic pheno-tin-1 [44], and it is a nonselective cation channel modu-
lated by calcium ions [46]. PKDREJ is located on chro- type [55], so it is likely that mutations in PKD1 and TSC2
act in an additive or synergistic manner in cystogenesis.mosome 22ql3.3 [47]. It encodes a 2253 amino acid
protein and shows approximately 45% similarity to poly- Nonsense, missense, and frameshift mutations have been
found throughout the PKD2 gene in ADPKD2 families,cystin-1 (corresponding to the predicted TM region and
the REJ module) and to polycystin-2 (corresponding to with approximately 50 mutations described to date [56].
Detection of these mutations has been straightforwardthe six TM region) [48]. PKD2L2 (accession AF118125),
located on chromosome 5q3, encodes a protein of 613 because of the single-copy structure of the gene. As in
the case of PKD1, the majority of these mutations areamino acids and is approximately 65% similar to polycys-
tin-2, but it appears to lack the EF hand and coiled-coil again unique in nature, although recurrent mutations in
unrelated families are more common. Recently, muta-regions. PKDL, PKDREJ, and PKD2L are not linked
to ADPKD in families that show no clear linkage to tional analysis of renal cyst-derived DNA of a patient
with a known germline mutation in PKD1 revealed so-either the PKD1 or PKD2 locus [44, 45, 47].
Mutations. Identifying mutations in PKD1 is compli- matic mutations not only in the other PKD1 allele in
certain cysts, but also in the PKD2 gene in other cystscated by the presence of the homologous genes. Screen-
ing for mutations in ADPKD patients therefore was ini- [57]. This trans-heterozygous state is consistent with the
proposition that the two gene products are involved intially limited to the 39 single copy region of the gene,
and 35 mutations have so far been described in this a signaling pathway, interruption of which leads to cyst
formation. These findings also suggest that combinedsegment which represents approximately 20% of the
gene [reviewed in 49]. Using a variety of techniques, haploinsufficiency at each locus can lead to cyst forma-
tion, perhaps through formation of dysfunctional hetero-including the protein truncation test [50], long-range
PCR (in which one of the primers is anchored in the meric complexes.
The mutational mechanism: One or two hits? Since allsingle-copy region [33, 51, 52]), and primers based on
rare differences in PKD1 and HG sequences [29, 53], epithelia of an ADPKD patient contain the same germ-
line mutation, why do cysts arise from fewer than 1%researchers have detected 29 additional mutations in the
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Fig. 2. Cyst formation as predicted by the
two-hit (A) and one-hit (B) hypotheses. In the
two-hit model, a random second somatic hit
in a cell (shaded), that already has a germline
mutation, is required for cyst initiation. In the
one-hit model, cells that have the germline
mutation (white) are phenotypic (that is, have
increased proliferation index) through a dose
effect. Increased proliferation then increases
the chances of somatic second hits, which may
not be limited in all cases to the remaining
PKD allele. Microscopically heterogeneous
cysts, formed by single- and double-hit mutant
cells, would result.
of all nephrons? Several groups screened genomic DNA count for the number of cysts that can develop in both
kidneys (,1% of all nephrons). The higher frequencyfrom single renal or hepatic cysts for loss of heterozygos-
ity (LOH, which detects large chromosomal deletions) and earlier onset of the type-I form of ADPKD would
be attributed to the proposed higher mutability of theand/or somatic mutations using intragenic or microsatel-
lite markers, single-stranded conformational polymor- PKD1 gene in this model [58].
Other observations are not readily explained by thephism analysis (SSCP), and sequencing. Approximately
10% to 25% of individual renal cysts analyzed showed two-hit mutational model, however. First, in view of the
large number of inactivating mutations in PKD1 andLOH of microsatellites from within or adjacent to the
“normal” PKD1 [58–60] or PKD2 alleles [58, 61, 62]. PKD2 detected to date, the two-hit hypothesis would
predict that very few if any of the cysts would express theAdditional unique mutations were found by SSCP and
sequencing, even in cysts that did not show LOH, in- respective protein. Just the opposite is observed, however.
The vast majority of ADPKD1 or ADPKD2 cysts reactcreasing the percentage of somatic mutations in the
“wild-type” allele to approximately 40%. Targeted dis- strongly with antibodies directed against the respective
protein [68–70]. One could explain this discrepancy ifruption of both alleles of Pkd1 [63, 64] or Pkd2 [65, 66]
in mice also leads to cyst formation in utero. Mice double the somatic second hit preserves the antibody-binding
site in the protein. However, strong immunostaining forheterozygous for a null Pkd2 allele and an unstable allele
Pkd2WS25 (which often recombines somatically to form a polycystin-1 [28] or polycystin-2 [70] is seen in a majority
of cysts, even when the antibodies used do not react withnull allele) develop renal cysts by 6 to 10 weeks of age
[66], and at a higher frequency than mice heterozygous the product of the respective germline mutation. Second,
recently generated mice transgenic for a human PKD1-for either allele. These findings suggest that, as in some
forms of inherited cancers [67], a second somatic “hit” encoded functional polycystin-1 developed renal cysts
(abstract; Pritchard et al, J Am Soc Nephrol 10:424A,in the normal PKD1 or PKD2 allele is required for cyst
initiation in a patient with ADPKD (Fig. 2). The number 1999). This observation cannot be readily explained by
the loss-of-function model predicted by the two-hit hy-of the somatic second hits is believed to be high to ac-
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pothesis. Third, increased proliferation rates have been null allele, also develop kidney and liver cysts [65]. The
lack of vascular lesions in these two models strengthenedfound even in non-cystic tubular epithelium in ADPKD
[71]. In addition, while LOH in PKD1 or PKD2 has been the belief that the vascular pathology in ADPKD is prin-
cipally related to the frequent occurrence of hypertension.detected in cyst epithelium, the specificity of this obser-
vation has not been rigorously established; LOH oc- We have generated a third animal model of ADPKD
by introducing a different type of mutation in the mousecurred at a limited number of other loci on DNA derived
from cysts [59, 62]; in one instance, interestingly, LOH Pkd1 locus [64]. In the mutant allele, PkdL, portions of
exons 43 and 45 and all of 44 are replaced by the neooccurred at an apparently unrelated locus [59].
Cystogenesis in ADPKD alternatively could be initi- cassette, and we introduced a stop codon at the end of the
remaining segment of exon 43. The mutant mouse poly-ated by a one-hit mechanism. In this model, haploinsuf-
ficiency in PKD1 or PKD2 provides the cell with a certain cystin-1 is expected to terminate after L3946 (equivalent
to L3955 in humans). Generalized edema, vascular leaks,growth advantage, the magnitude of which could vary
as a function of the nature of the germline mutation. and hemorrhages were the major phenotypic findings
observed in homozygous (Pkd1L/L) but not heterozygousSomatic second hits in PKD1, PKD2, or in one or more
interacting partners occur subsequently, and might fur- animals in this model. The focal hemorrhages expanded
with time to involve the whole animal, culminating inther increase the growth advantage of the mutant cell,
allowing a clonal expansion of that lineage in the ex- death at embryonic day (E) 15.5. Nephrogenesis was
normal, as in the other two models, but cysts soon ap-panding cyst. The frequency of somatic mutations is rela-
tively high in renal epithelium and increases with age peared in developed glomeruli and tubules by E14.5.
Vascular leaks were observed by E12.5 in macroscopi-[34]. This might explain why many unique somatic PKD1
or PKD2 mutations are observed in ADPKD cysts. This cally normal blood vessels. This was shown when we
micro-injected fluorescent 70 kD dextran in the cardinalmulti-step sequence of events can explain clonality in
cysts with demonstrated somatic second hits [58]. It also vein of live E12.5 embryos and age-matched wild-type
littermates. In the homozygous mutants, fluorescent dex-can explain the increased proliferation found in non-
cystic epithelium [71]. Functional inactivation of the nor- tran was found between the endothelial cell lining of
the vessel and in the subendothelial region; in wild-typemal polycystin-1 by the product of the germline mutant
allele can occur through a dominant effect, such as the animals, the dextran remained intravascular (Fig. 3) [64].
The early embryonic lethality and the vascular lesionsformation of an inactive protein complex or trapping of
the normal allele intracellularly, and could explain the distinguish our animal model of ADPKD from the one
reported by Lu et al [63]. A genetic background effectvariable onset and disease severity in ADPKD. Abun-
dant intracellular, but not cell surface, expression of poly- is an unlikely explanation for the observed differences
in disease severity and phenotype. The findings indicatecystin-1 has been reported in ADPKD-derived renal tis-
sue [68]. A 1998 study also found that mice heterozygous that the nature of the PKD1 mutation plays an important
role in the phenotypic heterogeneity observed in ADPKD,for a null PKD2 allele have a small number of cysts and
are more likely to die prematurely from nonrenal causes and we believe that they suggest a critical role for poly-
cystin-1 in the structural integrity of blood vessels, thethan are wild-type animals [65]. Older mice heterozygous
for a mutant Pkd1 allele also develop cysts [72]. Mice major theme of this Forum.
A vascular phenotype also was observed in a Pkd2have a lower general mutation frequency than do hu-
mans, so it is likely that the wild-type allele is normal in null mouse model [66]. Approximately 50% of Pkd22/2
embryos at E13.5 or later exhibited progressive total-these animals, but direct evidence is not yet available.
New animal models. In two previous animal models body edema and focal hemorrhages; death occurred in
utero between E13.5 and parturition. The vascular hem-of ADPKD caused by mutations in mouse Pkd1 or Pkd2,
the disease phenotype was epithelial in nature, consisting orrhages were attributed to the invariant ventricular sep-
tal defect and the variable atrial septal defect. Hemor-of bilateral renal cysts and variable cysts in other ductal
organs. In the first animal model, a truncation mutant, rhage, however, is not a common or an expected outcome
of ventricular septal defects [73–78]. Although edemaPkd1D34, in which exon 34 was replaced with a neo cas-
sette, was generated using homologous recombination. can be seen secondary to cardiac failure or to the increased
pulmonary circulation associated with ventricular septalHomozygous animals die perinatally because of pulmo-
nary hypoplasia, which is believed to result from oligohy- defects, edema does not occur before birth. These find-
ings suggest that the observed hemorrhagic phenotypedramnios and abdominal distension produced by enlarged
kidneys. Cardiac development was normal. Homozygous- in the Pkd2 null embryos might well be due to a primary
abnormality in the blood vessels, as in the case of thedeficient mice had massive glomerular, renal tubular, and
pancreatic cysts [63]. Mice homozygous for an unstable PkdL/L embryos.
Subcellular localization. Both polycystin-1 and -2 arePkd2WS25 allele, which undergoes somatic inactivation by
intragenic homologous recombination to produce a true ubiquitous proteins expressed in most tissues tested. Poly-
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Fig. 3. Vascular leak in Pkd1L/L mouse em-
bryos. Tissue section from an E12.5 wild-type
(a, b) and age- and litter-matched (Pkd1L/L)
(c, d) mouse embryos microinjected while alive
with fluorescent 70 kD dextran in the anterior
cardinal vein. Tissue sections were examined
under a fluorescent microscope. Fluorescent
dextran is retained intravascularly in wild type
(a, b, arrows), and is absent from the basolat-
eral side of the lining endothelium (b, arrows).
In contrast, dextran has leaked into the extra-
vascular interstitium (c, arrows), and is seen
at intercellular junctions (d, arrowhead) and
subendothelially (d, arrows) in the Pkd1L/L
embryo. Scale bar 5 10 mm in a, c, and 5 mm
in b, d. Modified from [64].
cystin-1 is expressed at the morula and blastocyst stages (CD31), an endothelial cell-cell junction protein, is also
found in cultured human umbilical vein endothelium [69].in the mouse [79]. Pkd1 mRNA is expressed in the pri-
mordial ectoderm, mesoderm, and endoderm layers and Punctate and linear staining for polycystin-1 also was
present at the apical pole of renal tubular epithelium [68].in the condensing pulmonary, metanephric, and dermal
mesenchyme. Polycystin-1 is detected in the branching In perpendicularly sectioned cells, a discrete apicolateral
membrane distribution is prominent; in tangentially sec-ureteric bud, the S-shaped and comma-shaped bodies,
the developing proximal and distal tubules, the collecting tioned cells, a thin bright apicolateral fishnet-like pattern
is seen around the cell circumference. Some stainingduct, and the uroepithelium [28, 68–70, 80, 81]. It is also
found in visceral and parietal epithelium of Bowman’s also is seen in the basolateral membrane regions. This
pattern is characteristic of proteins distributing to apical/capsule [68, 82] and in other fetal ductal epithelia (sali-
vary, bronchial, mammary, pancreatic, biliary, and epi- lateral cell junctions such as ZO-1 [a member of the
membrane-associated guanylate kinases (MAGUK) pro-thelial lining of reproductive organs). Its expression de-
clines as cells differentiate. In the normal adult kidney, tein family], occludin, and claudins [84, 85]. Double stain-
ing of the same tissues with an antibody to ZO-1 and tothe collecting ducts and intercalated cells were positive;
however, the protein is re-expressed in proximal renal polycystin-1 showed a considerable overlap of the two
proteins (abstract; Brown et al, J Am Soc Nephrol 9:371A,tubules following ischemia (abstract; Brown et al, J Am
Soc Nephrol 9:371A, 1998). Polycystin-1 also is expressed 1998). It is interesting that the junctional expression of
polycystin-1 is reduced in ischemic kidneys, where apicalin the brain, endothelia, smooth muscle cells, and cardiac
and skeletal muscle [68–70, 80]. Polycystin-2 has a tissue junctional complexes are known to disassemble follow-
ing ischemia, and is increased during the recovery phase.distribution in humans that is very similar to that of poly-
cystin-1. It is expressed in the developing epithelial struc- It might be relevant in this regard that cyst formation
in the two Pkd1 knockout models [63, 64] occurs in thetures of the kidney, pancreas, liver, lung, bowel, and re-
productive organs, as well as in the brain, myocardial and proximal nephron, where tight junctions possess only one
junctional strand. More recently, polycystin-1 was co-endocardial cells, vascular smooth muscle, and endothe-
lium of arteries and veins [70]. Co-localization of the two localized with the adherens junction proteins E-cadherin
and a- and b-catenin in human fetal kidney sections [86].proteins has been shown in epithelial structures of the
kidney [70] as well as in the adult male sensory neurons In this study, polycystin-1 co-localized very well with
a-catenin and less so with E-cadherin and b-catenin.in C. elegans [83]. These data suggest that the demon-
strated in vitro interaction between these two proteins Alpha-catenin can associate with ZO-1 [85], E-cadherin
can distribute widely on the lateral membranes [87], andis biologically significant, and that these two proteins act
in concert in a common signal transduction pathway. ZO-1 can localize to adherens cell junctions [84]. A third
study suggested that basolateral polycystin-1 is localizedWe entertained the possibility that the endothelial and
epithelial defects observed in Pkd1L/L mutant mice result at focal adhesions in cultured renal epithelial cells that
are allowed to attach to collagen [88]. Polycystin-2 alsofrom interference with a common cellular process that
normally requires polycystin-1. To begin to define the is found in the plasma membrane (apically and basally)
in human fetal renal tubular cells [70], but recombin-nature of this process, we examined the distribution of
polycystin-1 in normal rat renal blood vessels. Polycystin-1 ant forms also have been found in the endoplasmic reti-
culum [43].was primarily expressed in a regular punctate pattern at
the apical pole of endothelial cells from arterioles. Con- Immunoperoxidase staining of tissues from the Pkd1L/L
embryos revealed that the mutant polycystin-1 also issiderable co-localization of polycystin-1 with PECAM-1
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expressed in the vasculature and renal tubules as in the In summary, much has been learned about the genetic
basis of ADPKD, and new animal models are beginningwild type [64]. Localization of the mutant tail-less poly-
cystin-1 in the kidney was apicolateral in distribution. to elucidate the cell biology and underlying pathobiology
of this disease. The structure of polycystin-1 and the sharedStudies are in progress to define the membrane subdo-
main localization of this mutant. It is interesting that loss homology region among polycystins are reflective of a
novel potential link between adhesion and ion channelof the E-cadherin tail does not affect homotypic adhesion
or its localization at adherens junctions, but E-cadherin activities, which is utilized by cells in maintaining their
terminally differentiated state. The subcellular distribu-tail loss does lead to increased junctional permeability
[89]. It is unclear at present whether the broad distribu- tion of polycystin-1 and the leaky vascular phenotype in
PkdL/L mice suggest that ADPKD is a disease of cell-celltion of wild-type polycystin-1 in lateral (tight junctions,
adherens junctions) and basolateral membranes (focal junctions. Further work is required to establish the pre-
sumptive adhesive and ion channel activities of polycys-contacts) is a reflection of variability in epitope exposure
for the respective antibody used, the tissue source and tins, and to decipher how these activities are utilized to
maintain the structure and function of cell-cell junctions.fixation method, or cell culture conditions. It remains
possible that this distribution pattern is physiologically
relevant, in view of the dynamic nature of the different
QUESTIONS AND ANSWERS
types of cell junctions, their interdependence [84], and
Dr. Nicolaos E. Madias (Executive Academic Dean,their differential regulation in response to develop-
Tufts University School of Medicine, Boston, Massachu-mental and differentiation stimuli [87].
setts): Are the known mutations in the human PKD-1Role of cell-cell junctions in cell growth and differentia-
gene targeted to a certain region of the gene? If so, didtion. Cell-cell junctions are important determinants in
you position the mutation in your mouse model in thatcell growth and differentiation, processes that are abnor-
region?mal in ADPKD. TGF-a, for example, abrogates gluco-
Dr. Arnaout: Mutations in the PKD1 or PKD2 genescorticoid-induced growth inhibition through disruption
are distributed throughout the respective genes. Our mu-of tight junctions [90]. Hepatocyte growth factor/scatter
tation was introduced in the 39 region of the gene, whichfactor (HGF/SF)-induced loosening of tight junctions fa-
corresponds to the C-terminal non-duplicated protein seg-cilitates migration of epithelial cells during wound healing
ment. Several mutations occur in this region in humans.[91]. Increased proliferation of epithelial and endothelial
Dr. Madias: You noted that polycystin-1 is expressedcells as well as expression of hepatocyte growth factor,
in cardiocytes. It is interesting that normotensive adoles-vascular permeability growth factor [92], and endothelin-1
cents and young adults with ADPKD can have increased[93] result from disruption of adherens junctions. Dro-
left-ventricular mass as compared with matched controls.sophila embryos homozygous for null mutants of the dlg
Did you observe such an abnormality in your model?gene, a tumor suppressor homologue of ZO-1, display loss
Dr. Arnaout: We have not measured left-ventricularof septate junctions, overgrowth, and loss of cell polarity
mass in our mutant and wild-type embryos. It remains[reviewed in 64]. Also, vulval cells from C. elegans with
possible that such differences do not occur at the embry-a mutation in LIN2, an invertebrate MAGUK member,
onic stage. A conditional Pkd1 knockout mouse modelare not properly polarized and do not differentiate [re-
will likely be more appropriate in addressing potentialviewed in 64]. The phenotype of PkdL/L embryos reflects
early changes in cardiac mass.a novel role for polycystin-1 at apicolateral junctions.
Dr. John T. Harrington (Dean, Tufts UniversityIt might act in a signaling pathway, coupling growth
School of Medicine): You’ve told a fascinating story re-promoting or adhesion-triggered signals to ion channel
lating the patient’s vascular disease to the genetic defect.activity, thus modulating cell growth and differentiation.
But the coronary angiogram in this patient appears toAlternatively, polycystin-1 might serve as a molecular
show typical arteriosclerosis. Using your hypothesis, isscaffold, facilitating the assembly of protein complexes
this due to vascular leakage? How do you leap from athat are necessary for the maintenance of polarized epi-
vascular leakage phenomenon to the typical arterioscle-thelium or endothelium. Interruption of such a function
rosis seen in this and other patients?in epithelia might contribute to the abnormal prolifera-
Dr. Arnaout: I do not believe that atherosclerosis intion and differentiation that characterizes ADPKD epi-
this patient is due to a vascular leak. Vascular leak is onlythelium. Interference with homologous or heterologous
observed in our Pkd1L homozygous embryos—hetero-cell-cell junctions (such as those between vascular smooth
zygous animals are phenotypically normal. Patients withmuscle cells or between these cells and the endothelium-
ADPKD have early diastolic dysfunction, vascular scle-myoendothelial junctions [94]) could also weaken the blood
rosis, and high blood pressure that can increase athero-vessel wall directly, or indirectly through released growth
sclerosis. Abnormal polycystins expressed in the vascularfactors and cytokines acting on endothelium/vascular
smooth muscle in a paracrine or juxtacrine way. smooth and cardiac muscles could be causative in the
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cardiovascular lesions of ADPKD; the molecular details gap junction appears to be intact, have you excluded
the presence of endothelial fenestrae or transcellularremain to be worked out.
Dr. Ronald D. Perrone (Division of Nephrology, channels as the cause of increased vascular permeability?
Dr. Arnaout: No embryonic lethality occurred inNew England Medical Center): I have several questions
related to the genetic mechanism of PKD. Does loss mice with targeted disruption of the three nitric oxide
synthase (NOS) isoforms either alone or in combinationof function or another genetic mechanism lead to the
abnormal events? Following on that, as you know, in [reviewed in 96], and this finding argues against a role
for NO in the observed vascular leak in our animal model.the human disease, certain families have intracranial an-
eurysms and other families don’t; obviously, we’d be Nitric oxide is critical, however, post-developmentally
in host response to injury. For example, endothelium-very interested in genotype/phenotype correlations. We
know that some mutations lead to total deletion of the derived NO is involved in vascular remodeling and angi-
ogenesis in adult mice. Its potential role in the diastolicpolycystin gene.
Dr. Arnaout: The finding that mice homozygous for dysfunction, hypertension, and formation of aneurysms
in ADPKD, probable manifestations of impaired cross-null mutations in either Pkd1 or Pkd2 develop ADPKD
indicates that homozygous loss of function of polycystin-1 talk between endothelium and vascular smooth muscle,
merits study. In regard to your second question, prelimi-or -2 is causative. The recent animal data suggest that the
heterozygous state is also phenotypic, with the disease nary electron microscopic examination of tissue sections
from our knockout animals did not reveal endothelialseverity increased when both alleles for Pkd1 or Pkd2
are inactivated. Data from the new animal models also fenestrae. Also, it is well known that increased vascular
permeability can occur across normal-appearing tightargue that the nature of the mutation in Pkd1 or Pkd2
plays an important role in the genesis of the vasculopa- junctions.
Dr. Andrew S. Levey (Chief, Division of Nephrology,thy. We therefore expect that genotype/phenotype corre-
lations will be of value in evaluating phenotypic differ- New England Medical Center): Please tell us a little bit
more about the heterozygote that is phenotypically nor-ences in ADPKD. In support, Hateboer et al compared
the clinical phenotypes of 10 large Welsh families, each mal. Presumably, our patients with autosomal dominant
PKD are heterozygotes. Why doesn’t the heterozygotewith a unique disease-associated PKD-1 haplotype, and
found interfamilial differences in a number of clinical develop cysts? Does the homozygous knockout mouse
develop cysts?parameters, including the degree of renal insufficiency
[95]. Watnick et al also identified a 2bp deletion (5224del2) Dr. Arnaout: Our homozygous knockout embryos
develop renal and pancreatic cysts. We have not yetin exon 15 of PKD1, a frameshift mutation that leads
to a predicted truncated protein, in three apparently observed renal cysts in our heterozygotes that are up to
one year of age. As I stated, in another PKD1 knockoutunrelated families with intracranial aneurysms and/or
early-onset ADPKD [53]. The nature of the PKD muta- model, heterozygotes developed renal cysts at an older
age. It is not yet known whether somatic second hits aretion also might affect the phenotype indirectly, by modi-
fying, for example, the proliferation rate and therefore required in this setting.
Dr. Levey: May I ask a follow-up question on thethe rate of somatic second hits in the normal allele. The
genotype/phenotype correlation is not straightforward, expression of genes in humans? Not all patients with
tuberous sclerosis develop renal failure, but some do.however, as phenotypic differences are commonly ob-
served between family members with the same germline In the patients who do develop renal failure, is there
mutation in both the PKD1 gene and the tuberous sclero-mutation, suggesting that additional factors such as gene
modifiers are involved. sis gene?
Dr. Arnaout: Yes. Significant renal cystic disease inDr. Andrew J. King (Division of Nephrology, New
England Medical Center): My understanding of endothe- TSC2 patients reflects concomitant constitutional dele-
tions in PKD1 in the majority of cases [55]. Also, signifi-lial permeability is that it relates to tethering between the
two cells and is an active process relating to intracellular cant cystic disease has not been documented in affected
members of TSC1 (chromosome 9 linked) families.MAP kinases and phosphatases. Have you assessed
whether these intracellular enzymes are disrupted in Dr. Levey: What accounts for the greater severity of
cystic disease in patients with combined tuberous sclero-your genetically engineered animals?
Dr. Arnaout: We do not yet know the nature of the sis and ADPKD?
Dr. Arnaout: The molecular basis for the greaterintracellular downstream signals that are interrupted as
a result of the introduced Pkd mutations. severity of cystic disease in patients with both tuberous
sclerosis and ADPKD is not known. TSC2 encodes tu-Dr. Madias: I want to follow up on Dr. King’s ques-
tion. The endothelial nitric oxide system is implicated in berin, a cytosolic protein with GTPase-activating protein
(GAP) activity, which also forms a complex with hamar-the maintenance of vascular integrity. Does your model
have an abnormality in this system? Also, given that the tin, the product of TSC1 [97]. Tuberin has been linked
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to cell cycle regulation and differentiation [98]. I suggest patients with polycystic kidney disease? One patient will
have a normal liver and no cysts anywhere, while anotherthat combined mutations in PKD1 and TSC2 produce
a synergistic positive effect on cell proliferation, thus patient with a comparable level of renal function will
have many large cysts within the liver. What accountsinducing or increasing renal cyst formation.
Dr. Harrington: I’d like to follow up on Dr. Levey’s for that?
Dr. Arnaout: Mice homozygous for the Pkd1del34 orquestions. Do patients with tuberous sclerosis have the
same severity of vascular disease as do patients with PKD? Pkd1L alleles or for null mutations in Pkd1 or Pkd2
develop renal and pancreatic cysts at the embryonic stageDr. Arnaout: Patients with pure tuberous sclerosis
do not develop the vasculopathy seen in ADPKD. Car- but not liver cysts [63, 64, 66]. These findings suggest that
liver cysts perhaps take longer to develop. Mice homozy-diovascular involvement is limited to angiomyolipomas,
angiofibromas, and cardiac myomas. gous for the unstable Pkd2WS25 allele, which somatically
recombines into a null allele, are viable and develop liverDr. Harrington: What about patients with tuberous
sclerosis and renal failure? cysts by one to three months of age. Mice heterozygous
for Pkd1del34 or Pkd2null develop occasional renal and liverDr. Arnaout: As I mentioned, patients with tuberous
sclerosis and renal failure due to cystic disease have a cysts but at an older age [66, 72]. Mice double heterozy-
gous for a Pkd2null and Pkd2WS25 develop cysts soonerconcomitant mutation in PKD1, and are therefore ex-
pected to develop the vasculopathy of ADPKD. [65], suggesting that the somatic second hit increases
liver cyst formation. We have not yet observed liverDr. Harrington: You talked about the increased pro-
liferative rate induced or associated with polycystin. Do cysts in our Pkd1L heterozygotes. Thus, the nature of the
genetic mutation and of somatic second hits appears toany of the vascular endothelial growth factors—either
inhibitory or pro-active, as we say these days—have any contribute to the genesis of liver cysts. Additional factors
must be involved, however, as cystic liver disease tendsinfluence on the proliferative rates?
Dr. Arnaout: The increased proliferation in ADPKD to be more severe in females [reviewed in 1], and less
severe in patients with combined ADPKD and cysticis based on studies in human renal cystic tissue. This
phenomenon has not yet been assessed in any of the fibrosis [100].
new mouse models. There are no studies to my knowl-
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